Advertisement

CEVEC Pharmaceuticals introduces CAP-T transient expression system for serum-free, high yield protein production. Authentic human post-translational modifications, especially with complex and highly glycosylated proteins, are key features and make it an ideal tool for screening, assay development, target validation, and lead optimization. CAP-T cells are based on CAP cells and match their positive features with regard to comprehensive documentation, safety, non-tumor origin, and growth as suspension culture in serum- and protein-free media. CEVEC Pharmaceuticals GmbH, +49 (0)2 21- 46 02 08 00, www.cevec-pharmaceuticals.com
Advertisement
Advertisement